Mr. Craig Goodwin reports

NATURALLY SPLENDID ENTERS INTO EXCLUSIVE DISTRIBUTION AGREEMENT WITH SWISS COMPANY FOR HEMP-DERIVED PRODUCTS

Naturally Splendid Enterprises Ltd.'s wholly owned United States subsidiary, Naturally Splendid USA, has entered into an exclusive sales and distribution agreement for North America with Medropharm GmbH, a biotechnology company located in Kradolf, Switzerland. Medropharm specializes in the production, extraction, research and formulation of raw materials and products derived from industrial hemp. Under the agreement, Naturally Splendid will have the exclusive rights to market and distribute in North America an edible, cannabidiol-rich hemp powder, as well as the non-exclusive rights to market and distribute hemp-derived cannabinoid extracts and formulations globally. The products contain naturally occurring cannabidiol, a non-psychoactive cannabinoid prevalent in industrial hemp strains of cannabis sativa. The term of the initial exclusive distribution agreement is for two years. Pursuant to the agreement, Naturally Splendid will be permitted to sell the products to Medropharm's existing clients. Naturally Splendid is required to purchase 2,000 kilograms of the hemp powder in the first year and 3,000 kilograms in the following year to accommodate Medropharm's existing product demands, as well as its own industry prospects.

Medropharm's industrial hemp is sustainably grown on over 3,500 hectares under strict European Union regulations with constant monitoring to minimize the environmental impact, and ensure the highest quality of raw materials. From seed through product development, the raw materials are analyzed to ensure consistency in quality, safety and composition. The products are manufactured and tested in facilities with U.S. FDA (Food and Drug Administration), ISO (International Organization for Standardization), and CGMP (current good manufacturing practices) certifications, which is a rare find in this burgeoning industry.

Chief executive officer, Craig Goodwin, expressed: "Naturally Splendid is thrilled to have found a partner like Medropharm with a similar focus on quality and accountability. We are most fortunate to start this exclusive distribution agreement with Medropharm, as it allows us to continue sales of the Medropharm products in the U.S. to clients that previously purchased the products from Medropharm directly. It is our intention to build on that existing clientele and increase sales volumes significantly. We remain committed to maximizing the multiple revenue streams available from this one amazing plant."

Medropharm's chief marketing officer, Patrick Widmer, states: "We are delighted to partner with Naturally Splendid for high-volume distribution of our hemp-derived products. We share the same strategy focused on creating an industry standard for transparency and quality for our consumers. Our cultivation and inventory are sufficient to allow Naturally Splendid to generate annual sales of our cannabidiol products at approximately $10-million (U.S.). We are confident that Naturally Splendid, through focused efforts, can grow annual sales of the products to 10 tons annually in the U.S. as the regulatory environment continues to evolve. There are many exciting future opportunities on the horizon for our partnership with Naturally Splendid, and we look forward to a prosperous relationship."

Naturally Splendid's manager of regulatory compliance, Katie Schmitt, states, "We have worked diligently securing the necessary legal opinions in the jurisdictions where we will be operating, both in Switzerland regarding the exportation of these cannabidiol products, as well as the markets in the U.S. where we will be importing the hemp-derived products and distributing them." The products that will be distributed throughout the U.S. do not violate the Controlled Substances Act, as they are derived from permissible parts of the industrial hemp plant. These quality ingredients are suitable components for food and cosmetic applications, and will be available for wholesale throughout the U.S. Other products will be available for distribution in jurisdictions in accordance with applicable regulatory guidelines.

About Medropharm GmbH

Medropharm is a biotechnology company that specializes in the production, extraction, research and formulation of raw materials and products derived from industrial hemp. Medropharm is committed to researching the medicinal plant cannabis sativa, and processing its components into high-quality inputs for the food, cosmetic and pharmaceutical industries. Medropharm is deeply involved in sustainable plant propagation and is currently developing new germplasms, and cultivation methods are intended to revolutionize the production of high-quality, naturally occurring cannabinoids. Medropharm's mission is to produce high-quality cannabinoids for the pharmaceutical and food industries by means of rigorous standards of production and quality control, and to become a world leader in the research, development, manufacture and distribution of cannabinoid-containing products.

We seek Safe Harbor.